All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The split, universal, and programmable (SUPRA) CAR system is a two-component receptor system consisting of a universal receptor with leucine zipper adaptor (zipCAR) on T cells and a separate scFv with leucine zipper adaptor (zipFv) molecule targeting specific antigens. This split "lock-key" structure of SUPRA CAR with leucine zipper adaptors was desighed to enhance the flexibility and controllability of CARs, which has several clinically relevant advantages over a rigid CAR system:
• Antigen targets of one set of zipCAR T cells can be switched, expanded and combined without further modification of the CAR T cells.
• The activities and toxicities of SUPRA CAR T cells can be controlled and fine-tuned.
• Signaling domains and effector cell types can be changed and combined.
Creative Biolabs provides customized SUPRA design and construction services. Please contact us for more detailed information.
There are currently no customer reviews or questions for A ZipCAR [BZip-41BB-CD3ζ], with a CAR Adaptor [Anti-CD56 Antibody scFv(Promiximab)-AZip], a SUPRA CAR System (CAR-NR-ZP576). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION